StockData

Arrowhead Pharmaceuticals vs Liquidia

ARWR and LQDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ARWR and LQDA compare

Arrowhead Pharmaceuticals is the larger company, worth 1.2 times as much as Liquidia ($6.1B against $5.1B).

Liquidia grew revenue faster over the last twelve months (2234% versus 16.8% for Arrowhead Pharmaceuticals).

Liquidia keeps more of each dollar of sales as profit, with a net margin of 30.7% compared with −47.8% at Arrowhead Pharmaceuticals.

Liquidia scores higher on the StockData Score (8 against 5 for Arrowhead Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricARWRLQDA
Size and price
Market cap$6.1B$5.1B
Share price$42.99$56.73
Change, 1 year4.2%102%
Change, 5 years−40.3%1280%
Beta (5Y)1.571.00
Employees711216
StockData Score
Total score58 (better)
Valuation score00
Growth score22
Performance score23 (better)
Health score13 (better)
Dividend score00
Valuation
P/E–40.8×
P/S9.1× (better)11.3×
P/B13.0× (better)26.0×
EV/EBITDA–28.2×
P/FCF–33.7×
FCF yield−1.2%3.0% (better)
Fair value$31.89$32.46
Margin of safety−34.8% (better)−74.8%
Growth
Revenue growth (TTM)16.8%2234% (better)
Revenue growth, 5Y average56.6%192% (better)
Profitability
Operating margin−33.8%37.4% (better)
Net margin−47.8%30.7% (better)
FCF margin−11.2%33.4% (better)
Return on equity−64.8%132% (better)
Financial health
Interest coverage−2.4×6.3× (better)
Current ratio5.90 (better)2.31
Altman Z-score1.6910.49 (better)
Piotroski F-score5 (better)4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions84.6%81.1%
Held by insiders4.0%19.5%
Insider net buying, 12 months−$36.9M (better)−$227M
Short interest, % of float8.5%24.3%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.